Dyadic (AMEX:DIL)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Dyadic Charts. Click Here for more Dyadic Charts.](/p.php?pid=staticchart&s=A%5EDIL&p=8&t=15)
Dyadic International, Inc. (AMEX:
DIL), a biotechnology company, announced today that on November 17,
2006, it entered into a definitive agreement with institutional
investors to purchase in a private placement 2,787,000 shares of common
stock at a price of $4.68 per share and warrants to purchase up to
557,400 shares of common stock for gross proceeds of $13,043,160. The
warrants will become exercisable on the 181st
day after being issued, expire three years thereafter, have an exercise
price of $6.33 per share and will be callable by the Company under
certain circumstances. Cowen and Company, LLC, acted as the exclusive
placement agent for the offering. The closing of the private placement
is subject to the approval of the listing of the shares and the shares
underlying the warrants by the American Stock Exchange and other
customary closing conditions.
“The net proceeds of approximately $12.3
million will greatly assist us in expanding our C1 Host Technology
development program that is fundamental to all of our businesses and, in
particular, is anticipated to aid in the development of large-scale
enzyme production systems and manufacturing processes for use in the
production of abundant low cost fermentable sugars from biomass,”
commented Mark Emalfarb, Dyadic’s President
and CEO. “Additionally, the net proceeds are
anticipated to help us strengthen the product pipeline for our Enzyme
business, accelerate the commercial launch of new products in pulp &
paper, animal feed and other areas, and expand R&D infrastructure as
well as our sales and marketing efforts.”
The securities offered in the private placement have not been registered
under the Securities Act of 1933, as amended (the “Act”)
or any state securities laws, and may not be offered or sold in the
United States absent registration, or an applicable exemption from
registration, under the Act and applicable state securities laws. Under
the purchase agreement, the Company has agreed to file a resale
registration statement on Form S-3 with the SEC covering the resale of
the shares of common stock issued at the closing and the shares of
common stock underlying the warrants.
About Dyadic
Dyadic International, Inc. is engaged in the development, manufacture
and sale of biological products using a number of proprietary fungal
strains to produce enzymes and other biomaterials, principally focused
on a system for protein production based on the patented Chrysosporium
lucknowense fungus, known as C1. Dyadic is applying its technologies
to produce enzymes for use in converting various agricultural products
(e.g. corn) and waste products (e.g. switch grass, wheat straw, sugar
cane bagasse, etc.) into fermentable sugars, which can then be used in
the production of traditional and cellulosic ethanol as well as other
products currently derived from petroleum. Dyadic's C1 technology also
is being developed to facilitate the discovery, development and
large-scale production of human antibodies and other high-value
therapeutic proteins. Dyadic currently sells more than 45 liquid and dry
enzyme products to more than 200 industrial customers in approximately
50 countries for the textile, pulp & paper and animal feed industries.
Cautionary Statement for Forward-Looking Statements
Certain statements contained in this press release are
"forward-looking statements." These forward-looking statements involve
risks and uncertainties that could cause our actual results, performance
or achievements to be materially different from any future results,
performance or achievements expressed or implied by such forward-looking
statements. For a discussion of these risks and uncertainties, please
see our filings from time to time with the Securities and Exchange
Commission, which are available free of charge on the SEC's web site at http://www.sec.gov,
including our Annual Report on Form 10-KSB for the year ended December
31, 2005, and our subsequent filings with the SEC. Except as required by
law, we expressly disclaim any intent or obligation to update any
forward-looking statements.
Dyadic International, Inc. (AMEX: DIL), a biotechnology company,
announced today that on November 17, 2006, it entered into a
definitive agreement with institutional investors to purchase in a
private placement 2,787,000 shares of common stock at a price of $4.68
per share and warrants to purchase up to 557,400 shares of common
stock for gross proceeds of $13,043,160. The warrants will become
exercisable on the 181st day after being issued, expire three years
thereafter, have an exercise price of $6.33 per share and will be
callable by the Company under certain circumstances. Cowen and
Company, LLC, acted as the exclusive placement agent for the offering.
The closing of the private placement is subject to the approval of the
listing of the shares and the shares underlying the warrants by the
American Stock Exchange and other customary closing conditions.
"The net proceeds of approximately $12.3 million will greatly
assist us in expanding our C1 Host Technology development program that
is fundamental to all of our businesses and, in particular, is
anticipated to aid in the development of large-scale enzyme production
systems and manufacturing processes for use in the production of
abundant low cost fermentable sugars from biomass," commented Mark
Emalfarb, Dyadic's President and CEO. "Additionally, the net proceeds
are anticipated to help us strengthen the product pipeline for our
Enzyme business, accelerate the commercial launch of new products in
pulp & paper, animal feed and other areas, and expand R&D
infrastructure as well as our sales and marketing efforts."
The securities offered in the private placement have not been
registered under the Securities Act of 1933, as amended (the "Act") or
any state securities laws, and may not be offered or sold in the
United States absent registration, or an applicable exemption from
registration, under the Act and applicable state securities laws.
Under the purchase agreement, the Company has agreed to file a resale
registration statement on Form S-3 with the SEC covering the resale of
the shares of common stock issued at the closing and the shares of
common stock underlying the warrants.
About Dyadic
Dyadic International, Inc. is engaged in the development,
manufacture and sale of biological products using a number of
proprietary fungal strains to produce enzymes and other biomaterials,
principally focused on a system for protein production based on the
patented Chrysosporium lucknowense fungus, known as C1. Dyadic is
applying its technologies to produce enzymes for use in converting
various agricultural products (e.g. corn) and waste products (e.g.
switch grass, wheat straw, sugar cane bagasse, etc.) into fermentable
sugars, which can then be used in the production of traditional and
cellulosic ethanol as well as other products currently derived from
petroleum. Dyadic's C1 technology also is being developed to
facilitate the discovery, development and large-scale production of
human antibodies and other high-value therapeutic proteins. Dyadic
currently sells more than 45 liquid and dry enzyme products to more
than 200 industrial customers in approximately 50 countries for the
textile, pulp & paper and animal feed industries.
Cautionary Statement for Forward-Looking Statements
Certain statements contained in this press release are
"forward-looking statements." These forward-looking statements involve
risks and uncertainties that could cause our actual results,
performance or achievements to be materially different from any future
results, performance or achievements expressed or implied by such
forward-looking statements. For a discussion of these risks and
uncertainties, please see our filings from time to time with the
Securities and Exchange Commission, which are available free of charge
on the SEC's web site at http://www.sec.gov, including our Annual
Report on Form 10-KSB for the year ended December 31, 2005, and our
subsequent filings with the SEC. Except as required by law, we
expressly disclaim any intent or obligation to update any
forward-looking statements.